Truvada (emtricitabine / tenofovir disoproxil)

€876.00
In stock
SKU
Truvada (emtricitabine / tenofovir disoproxil)

Truvada (emtricitabine / tenofovir disoproxil) is a medication used in combination with at least one other antiviral medicine for the treatment of human immunodeficiency virus type 1 (HIV-1) infection or prevention (PrEP).

How to buy Truvada (emtricitabine tenofovir): You can order Truvada (emtricitabine / tenofovir disoproxil) from TheSocialMedwork if the drug has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Infectiology HIV/AIDS
Marketing Authorisation Holder Gilead Sciences International Limited
Mode of Action Antiviral
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Strength 200mg/245mg milligram
Package 30 Tablets

What is Truvada (emtricitabine / tenofovir disproxil) for?

Truvada (emtricitabine / tenofovir disoproxil) is an antiviral medicine used in combination with at least one other antiviral medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS)1.

It is also used to help prevent sexually transmitted HIV-1 infection in adults who are at high risk of being infected (PrEP - pre-exposure prophylaxis). It is recommended for use in combination with safer sex practices, such as the use of condoms1,2, which may protect against other sexually transmitted infections (STIs) as well as against HIV infection.

How does Truvada (emtricitabine / tenofovir disproxil) work?

Each tablet of Truvada (emtricitabine / tenofovir disoproxil) contains two active substances, emtricitabine (200 mg) and tenofovir disoproxil (300 mg4,5, 245 mg3 or other4). Inside the body, tenofovir disoproxil is converted into the active substance tenofovir. Tenofovir and emtricitabine block the activity of the enzyme made by the virus to reproduce itself in the cells it has infected.

For the treatment of HIV-1 infection, Truvada, taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level. It does not cure HIV infection or AIDS, but it can prevent damages to the immune system and the development of infections and diseases associated with AIDS1.

For HIV-1 infection prevention (PrEP), it is expected that Truvada in the blood will stop the virus from multiplying and spreading from the site of infection in case the individual is exposed to the virus1.

Both active substances have been widely authorised separately since the early 2000s1,6,7.

Where has Truvada (emtricitabine / tenofovir disproxil) been approved?

Truvada (emtricitabine / tenofovir disproxil) was approved for the treatment of patients infected with human immunodeficiency virus type 1 (HIV-1) by, among others:

  • Food and Drug Administration (FDA), USA, August 2, 20042
  • European Medical Agency (EMA), European Union, February 21, 20051
  • Therapeutic Goods Administration (TGA), Australia, September 22, 20058

Approximately 10 years later (2012 by the FDA9, in 2016 by the EMA10 and TGA11) the approval has been extended to the use as pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Truvada (emtricitabine / tenofovir disproxil) taken?

The standard FDA dosage is4:

  • in adults and pediatric patients weighing more than or equal to 35 kg: one tablet 200 mg/ 300 mg of emtricitabine and tenofovir disoproxil fumerate once daily (equivalent to 200 mg emtricitabine/ 245 mg tenofovir disoproxil)

  • in pediatric patients weighing greater than or equal to 17 kg and able to swallow a whole tablet: one low strength tablet (100 mg/150 mg, 133 mg/ 200 mg, or 167 mg/ 250 mg based on body weight) once daily.

The TGA standard dosage is5:

  • 1 tablet 200 mg emtricitabine/ 300 mg tenofovir disoproxil  fumerate once daily (equivalent to 200 mg emtricitabine/ 245 mg tenofovir disoproxil).

The EMA standard dosage in adults and adolescents aged 12 years and older is6:

  • 1 tablet 200 mg emtricitabine/ 245 mg tenofovir disoproxil once daily (equivalent to 200 mg emtricitabine/ 300 mg tenofovir disoproxil  fumerate).

Warning: The kidney function should be monitored in all patients. Patients using Truvada for PrEP should be tested for HIV infection every 3 months.

Warning: Truvada (emtricitabine / tenofovir disproxil) used for a PrEP indication must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initial use and periodically during use. Drug-resistant HIV-1 variants have been identified with the use of Truvada (emtricitabine / tenofovir disproxil) for a PrEP indication following undetected acute HIV-1 infection. Do not initiate Truvada (emtricitabine / tenofovir disproxil) for a PrEP indication if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed.

Complete information about Truvada (emtricitabine / tenofovir disproxil) dosage and administration can be found in the official prescribing information listed in our resources section3,4,5.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects of Truvada (emtricitabine / tenofovir disproxil)?

Common side effects

The most common side effects in HIV-1 infected patients listed in the prescribing information include3,4,5:

  • diarrhoea
  • nausea (feeling sick)
  • fatigue
  • headache
  • dizziness
  • depression
  • insomnia
  • abnormal dreams
  • rash.

The most common side effects in HIV-1 uninfected people (PrEP) listed in the prescribing information include3,4,5:

  • headache
  • abdominal pain
  • weight decrease.

Serious side effects

The serious side effects listed in the prescribing information include:

  • lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including a component of Truvada
  • new onset or worsening renal impairment
  • decreases in bone mineral density (BMD)
  • immune reconstitution syndrome.

Use in specific populations

Women infected with HIV-1 should be instructed not to breastfeed.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information3,4,5.

More Information
Working ingredient emtricitabine / tenofovir disoproxil
Shipping method Standard (not temperature controlled)
Package 30
Therapeutic Area Infectious diseases
Infectiology HIV/AIDS
Indication HIV-1 infection treatment or prevention (PrEP)
Administration Oral
Mode of Action Antiviral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Gilead Sciences International Limited

HIV-1 infection treatment

The Food and Drug Administration (FDA), USA, European Medical Agency (EMA), European Union, Therapeutic Goods Administration (TGA), Australia, approvals of Truvada (emtricitabine/tenofovir disproxil) for HIV-1 infection treatment were based on studies that compared emtricitabine and tenofovir disoproxil with other antiviral medicines in HIV-1-positive treatment-naive adults. The study GS-01-9343,4,5 compared the combination of emtricitabine and tenofovir disoproxil with the combination of lamivudine and zidovudine (other antiviral medicines) both taken with another antiviral medicine (efavirenz) by patients with HIV-1 infection.

Results

The active substances in Truvada, emtricitabine and tenofovir disoproxil, were more effective than the comparator medicines in reducing the viral load1.

Eighty percent of the patients (total of 511) taking emtricitabine and tenofovir disoproxil achieved and maintained viral loads below 50 HIV-1 copies/ml by 48 weeks, compared with 70% of the patients taking the comparator medicines1.

HIV-1 infection prevention (PrEP)

The Food and Drug Administration (FDA), USA, European Medical Agency (EMA), European Union, Therapeutic Goods Administration (TGA), Australia, approvals of Truvada (emtricitabine / tenofovir disproxil) for HIV-1 infection prevention were based on two main studies which evaluated the addition of emtricitabine / tenofovir disoproxil to standard preventative measures for pre-exposure prophylaxis. This was done by comparing emtricitabine / tenofovir disoproxil with placebo in adults at high risk of sexually transmitted HIV-1 infection. Emtricitabine / tenofovir disoproxil resulted more effective than placebo for preventing HIV-1 infection. In both studies the level of protection depended on how well individuals adhered to the treatment program1.

Study iPrEx involved 2499 HIV-seronegative individuals with evidence of high-risk behaviour for HIV-1 infection3,4,5. In total, the study lasted 4,237 person-years (a person-year is a measurement combining the number of persons and their time contribution in a study12). Of the 1,224 people in the emtricitabine/tenofovir disoproxil arm 3.9% tested positive for HIV-1 infection compared with 6.8% individuals taking placebo1.

The second study (Partner PrEP) involved over 4,758 heterosexual couples with discordant HIV-1 infection status3,4,5. Of the individuals taking Truvada, 0.8% tested positive for HIV-1 infection over 1 year compared with 3.3% of those taking placebo1.

Shipping Type Standard
Shipping method Standard (not temperature controlled)
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, German, Italian, Lithuanian, Mandarin, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.